Browse the evidence

Defects in mitochondrial oxidative phosphorylation contribute to insulin resistance and β-cell apoptosis.

Addressing mitochondrial oxidative phosphorylation may improve insulin sensitivity.

There is a need for more high-quality, large, prospective controlled research to elucidate the role of dietary structure with different fat to carbohydrate ratios across the life cycle of diabetes.

Future research should focus on dietary ratios to better inform diabetes management strategies.

There was a statistically significant decrease in counselor feedback duration from the first to second quarter and from the second to third quarter.

Understanding the timing of feedback can help optimize counselor training and intervention design.

Abbott measurements were 12.9±0.1 mg/dl lower than Dexcom (p<0.0001).

Clinicians should be aware that different CGMs may provide varying glucose readings.

The reanalysis ignored the within-participant, repeated-measures structure of the data.

Understanding the importance of proper statistical methods is crucial for accurate dietary research interpretation.

The reanalysis reported incorrect statistical comparisons and optimistic p-values.

Practitioners should critically evaluate statistical results in dietary studies to avoid misinterpretation.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the United States food supply increased much more than population needs.

This suggests that dietary guidelines should address energy intake relative to needs.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

The genetic risk score (GRS) was associated with incident coronary heart disease (CHD) across cohorts, with a relative risk (RR) of 1.59 (95% CI: 1.41-1.79) for the highest quintile compared to the lowest.

Genetic risk factors significantly contribute to the likelihood of developing CHD, highlighting the importance of genetic screening.

No significant findings emerged in White women, African American men, or for the 8-10 week outcomes or for waist-to-hip ratio adjusted for body mass index (WHRadjBMI).

Practitioners should be cautious in generalizing findings across different demographic groups.

Receiving e-messages had no significant effect on adherence to low-carbohydrate or low-fat diets.

The e-message intervention did not enhance adherence to specific dietary plans, indicating a need for more effective strategies.

Households in low-income countries spend a considerable proportion of their income on food, approximately half.

Understanding food expenditure can help in designing interventions for better nutrition.

Early treatment with the DPP-4 inhibitor, sitagliptin, did not lead to better glycemic control than placebo and did not prevent posttransplant diabetes (PTD).

Practitioners should reconsider the use of sitagliptin for preventing PTD in kidney transplant patients.

The study failed to observe a statistically significant difference in the primary efficacy measure of ≥20 mg/dl difference in the 2-h OGTT at 3 months.

The lack of significant difference suggests that sitagliptin may not be effective in improving glucose tolerance in this population.

The potential effect of sitagliptin on blood glucose was lost by month 6 after treatment discontinuation.

This suggests that continuous treatment may be necessary to maintain glycemic control.

Monogenic obesity is rare and caused by mutations in a single gene.

Recognizing the rarity of monogenic obesity can help in accurate diagnosis and treatment.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist.

Understanding the mechanism can help in predicting the drug's effects and potential interactions.

Tirzepatide has been registered in multiple countries including the USA, UK, Canada, and Saudi Arabia.

This information is relevant for healthcare providers regarding the availability of Tirzepatide.

In 46% of the 104 studies analyzed, there was no information on the proportion of older individuals.

Practitioners should be cautious when applying findings from studies that do not include older populations.

Older patients were mostly underrepresented in the studies analyzed.

Findings may not be generalizable to older patients due to their underrepresentation.

The analysis found no significant differences in efficacy and safety of the drugs between age groups.

Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors appear consistent across age groups.

Major complication rates did not differ significantly between AOM users and the control group.

AOMs may be safely used preoperatively without increasing complication risks.

No significant differences in readmission rates, BMI, and total weight loss were observed at 6, 12, and 18 months of follow-up between groups.

Long-term outcomes may not be significantly improved by preoperative AOM use.